Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, today announced equity awards granted on May 11, 2015, that were previously approved …
Sarepta Therapeutics Inc (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, today reported financial results for the three months ended March 31, 2015, and …
Roth Capital analyst Debjit Chattopadhyay was out pounding the table on Sarepta Therapeutics Inc (NASDAQ:SRPT) Monday, reiterating a Buy rating and price target of $22, …
In a research report published Wednesday, Oppenheimer analyst Christopher Marai maintained an Outperform rating on Sarepta Therapeutics Inc (NASDAQ:SRPT) with a $45 price target, …
Christopher Marai of Oppenheimer is optimistic going into the Dystrophin Methodology Workshop on March 20, which will be hosted by the FDA-NIH. Subsequently, the analyst …
In a research report published this morning, Canaccord Genuity analyst Adam Walsh maintained a Hold rating on Sarepta Therapeutics Inc (NASDAQ:SRPT) with a $16 price …
In a research report published Friday, Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on Sarepta Therapeutics Inc (NASDAQ:SRPT) with a price target of $22, as the …
Cowen analyst Ritu Baral reiterated an Outperform rating on Sarepta Therapeutics (NASDAQ:SRPT) with a price target of $19, as the company announced data through Week 168 …
In a research report sent to investors today, Canaccord Genuity analyst Adam Walsh initiated coverage on shares of Sarepta Therapeutics (NASDAQ:SRPT) with a …
In a research report released this morning, Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on Sarepta Therapeutics (NASDAQ:SRPT) with a $22 price …
